Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual Meeting, taking place from September 15-18 in National Harbor, Md.

Below is the schedule for the poster presentations:

   

Date:

 Friday, September 16, 2016

Poster Presentation Time:

 5:30 p.m. – 6:30 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

 10
 

Title:

 Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super-Refractory Status Epilepticus
 
   

Date:

 Friday, September 16, 2016

Poster Presentation Time:

 5:30 p.m. – 6:30 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

 168
 

Title:

 Pharmacokinetics of SAGE-547 in Patients with Super-Refractory Status Epilepticus
 
   

Date:

 Friday, September 16, 2016

Poster Presentation Time:

 5:30 p.m. – 6:30 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

 172
 

Title:

 SAGE-547 (allopregnanolone injection) for the Treatment of Super-Refractory Status Epilepticus: Response and Relationship to Underlying Patient Characteristics
 
   

Date:

 Friday, September 16, 2016

Poster Presentation Time:

 5:30 p.m. – 6:30 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

 174
 

Title:

 Phase 1/2 Open-Label Data Suggest that Heterogeneity of Presentation and High Burden of Comorbid Illness Do Not Impact the Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus
 
   

Date:

 Saturday, September 17, 2016

Poster Presentation Time:

 5:30 p.m. – 6:30 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

 165
 

Title:

 Hemodynamic Properties of SAGE-547 in Patients with Super-Refractory Status Epilepticus: Results from a Phase 1/2 Clinical Trial
 

In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:

   

Date:

 Saturday, September 17, 2016

Time:

 12:00 p.m. – 1:00 p.m. EDT

Location:

 Gaylord National Resort & Convention Center, Maryland Ballroom C
 

Title:

 Diagnosis and Management of Super-Refractory Status Epilepticus
 

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.